Sonoma Pharmaceuticals, Inc. Business Operations Contracts & Agreements
28 Contracts & Agreements
- Agency Agreements (5 contracts)
- Collaboration Agreements (1)
- Distribution Agreements (9)
- Sales Agreements (4)
- Services Agreements (2)
- Supply Agreements (7)
- Amendment No. 1 to Distribution Agreement, dated October 17, 2024, by and between Sonoma Pharmaceuticals, Inc. and Medline Industries, LP (Filed With SEC on October 22, 2024)
- Distribution Agreement, dated August 19, 2024, by and between Sonoma Pharmaceuticals, Inc. and Medline Industries, LP (Filed With SEC on August 21, 2024)
- Form of Placement Agency Agreement (Filed With SEC on October 13, 2023)
- Exclusive Distribution and Supply Agreement, dated January 26, 2023, by and between Sonoma Pharmaceuticals, Inc. and Daewoong Pharmaceutical Co., Ltd (Filed With SEC on January 31, 2023)
- Non-Exclusive Distribution and Supply Agreement between Sonoma Pharmaceuticals, Inc. and Salus Medical, LLC dated January 19, 2022 (Filed With SEC on January 20, 2022)
- Exclusive Supply and Distribution Agreement between the Company and EMC Pharma, LLC, dated March 26, 2021 (Filed With SEC on March 31, 2021)
- Licensing and Distribution Agreement between Sonoma Pharmaceuticals, Inc. and Gabriel Science, LLC, effective December 14, 2020 (Filed With SEC on December 17, 2020)
- Exclusive Licensing and Distribution Agreement between Sonoma Pharmaceuticals, Inc. and Crown Laboratories, Inc., effective December 4, 2020 (Filed With SEC on December 10, 2020)
- Placement Agency Agreement entered into by and between Sonoma Pharmaceuticals, Inc. and Dawson James Securities, Inc., as representative, dated November 26, 2019 (Filed With SEC on November 29, 2019)
- Placement Agency Agreement entered into by and between Sonoma Pharmaceuticals, Inc. and Dawson James Securities, Inc., as representative, dated November 16, 2018 (Filed With SEC on November 21, 2018)
- Form of Placement Agency Agreement (Filed With SEC on November 16, 2018)
- Placement Agency Agreement entered into by and between Sonoma Pharmaceuticals, Inc. and Dawson James Securities, Inc. as representative of the placement agents, dated March 2, 2018 (Filed With SEC on March 6, 2018)
- At Market Issuance Sales Agreement, dated December 8, 2017, by and between Sonoma Pharmaceuticals, Inc. and B. Riley FBR, Inc (Filed With SEC on December 8, 2017)
- Distribution Agreement by and between Sonoma Pharmaceuticals, Inc. and G. Pohl-Boskamp GmbH & Co. KG, dated April 13, 2016 (Filed With SEC on June 28, 2017)
- EXCLUSIVE SALES AND DISTRIBUTION AGREEMENT (Filed With SEC on March 23, 2016)
- AMENDMENT NO. 1 TO SLA BRANDS, INC. SALES REPRESENTATION CONTRACT (Filed With SEC on February 16, 2016)
- SLA Brands, Inc. SALES REPRESENTATION CONTRACT (Filed With SEC on March 2, 2015)
- AMENDMENT NO. 1 TO SHARED SERVICES AGREEMENT (Filed With SEC on February 6, 2014)
- Licenseand Supply Agreement (Filed With SEC on September 24, 2013)
- SHARED SERVICES AGREEMENT (Filed With SEC on June 7, 2013)
- Licenseand Supply Agreement (Filed With SEC on June 7, 2013)
- ExclusiveDistribution and Supply Agreement (Filed With SEC on August 15, 2012)
- License,Exclusive Distribution and Supply Agreement (Filed With SEC on August 15, 2012)
- COLLABORATION AGREEMENT (Filed With SEC on August 3, 2012)
- DISTRIBUTION AGREEMENT (Filed With SEC on August 4, 2011)
- EXCLUSIVESALES AND DISTRIBUTION AGREEMENT (Filed With SEC on February 18, 2011)
- AMENDMENTNO. 3 TO REVENUESHARING, PARTNERSHIP AND DISTRIBUTION AGREEMENT (Filed With SEC on August 5, 2010)
- REVENUE SHARING DISTRIBUTION AGREEMENT (Filed With SEC on January 29, 2009)
